Xenon Pharmaceuticals Return on Investment 2012-2022 | XENE

Current and historical return on investment (ROI) values for Xenon Pharmaceuticals (XENE) over the last 10 years.
Xenon Pharmaceuticals ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $-0.08B inf%
2021-12-31 $-0.08B inf%
2021-09-30 $-0.07B inf%
2021-06-30 $-0.06B inf%
2021-03-31 $-0.04B inf%
2020-12-31 $-0.03B inf%
2020-09-30 $-0.03B -120.39%
2020-06-30 $-0.03B -63.49%
2020-03-31 $-0.04B -56.14%
2019-12-31 $-0.04B $0.10B -44.90%
2019-09-30 $-0.04B $0.09B -39.31%
2019-06-30 $-0.05B $0.10B -40.27%
2019-03-31 $-0.04B $0.11B -40.68%
2018-12-31 $-0.04B $0.12B -44.71%
2018-09-30 $-0.04B $0.13B -57.58%
2018-06-30 $-0.03B $0.06B -95.65%
2018-03-31 $-0.03B $0.03B -173.68%
2017-12-31 $-0.03B $0.04B -314.29%
2017-09-30 $-0.03B inf%
2017-06-30 $-0.03B inf%
2017-03-31 $-0.03B inf%
2016-12-31 $-0.02B inf%
2016-09-30 $-0.02B inf%
2016-06-30 $-0.02B inf%
2016-03-31 $-0.01B inf%
2015-12-31 $-0.01B inf%
2015-09-30 $-0.01B inf%
2015-06-30 $0.00B inf%
2015-03-31 $0.00B inf%
2014-12-31 $0.01B inf%
2014-06-30 $0.01B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.548B $0.018B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00